Market closed
Kenvue /$KVUE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kenvue
Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
Ticker
$KVUE
Sector
Trading on
NYSE
Industry
Personal Care Products
Headquarters
Employees
22,000
Website
Kenvue Metrics
BasicAdvanced
$45B
43.45
$0.54
-
$0.81
3.51%
Price and volume
Market cap
$45B
52-week high
$24.05
52-week low
$17.67
Average daily volume
15M
Dividend rate
$0.81
Financial strength
Current ratio
0.963
Quick ratio
0.564
Long term debt to equity
73.759
Total debt to equity
82.929
Dividend payout ratio (TTM)
150.68%
Interest coverage (TTM)
7.94%
Management effectiveness
Return on assets (TTM)
6.88%
Return on equity (TTM)
9.87%
Valuation
Price to earnings (TTM)
43.45
Price to revenue (TTM)
2.896
Price to book
4.63
Price to tangible book (TTM)
-5.85
Price to free cash flow (TTM)
33.675
Dividend yield (TTM)
3.47%
Forward dividend yield
3.51%
Growth
Revenue change (TTM)
0.07%
Earnings per share change (TTM)
-40.24%
3-year revenue growth (CAGR)
0.88%
3-year earnings per share growth (CAGR)
-23.68%
What the Analysts think about Kenvue
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kenvue stock.
Kenvue Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Kenvue Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Kenvue News
AllArticlesVideos
Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
Seeking Alpha·1 week ago
Buy 2 February S&P 500 Dividend Aristocrats Out Of 38 'Safer'
Seeking Alpha·2 weeks ago
Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kenvue stock?
Kenvue (KVUE) has a market cap of $45B as of February 27, 2025.
What is the P/E ratio for Kenvue stock?
The price to earnings (P/E) ratio for Kenvue (KVUE) stock is 43.45 as of February 27, 2025.
Does Kenvue stock pay dividends?
Yes, the Kenvue (KVUE) stock pays dividends to shareholders. As of February 27, 2025, the dividend rate is $0.81 and the yield is 3.51%. Kenvue has a payout ratio of 150.68% on a trailing twelve-month basis.
When is the next Kenvue dividend payment date?
The next Kenvue (KVUE) dividend payment date is unconfirmed.
What is the beta indicator for Kenvue ?
Kenvue (KVUE) does not currently have a Beta indicator.